MEMBER'S LOGINX
| Invalid Username / Password | ||||||||
| Invalid Captcha | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote
- Sector Info (List of nifty pharma Stocks)
- List of NIFTY Pharma Stocks
List of NIFTY Pharma
Stocks 
Here are the latest stock price details of the stocks in the NIFTY Pharma. For more detailed updates, check the latest NIFTY Pharma stock results and see the latest NIFTY Pharma long term chart.
Download Now: Exclusive Guide About India's Potentially Decade-Long $10 Trillion Bull Run...
| SCRIP | BSE PRICE (Rs) | NSE PRICE (Rs) | CHART | MORE INFO |
|---|---|---|---|---|
| AUROBINDO PHARMA | 1,131.15 2.50% | 1,131.30 2.53% |
|
More Info
|
| BIOCON | 307.00 5.25% | 306.40 5.06% |
|
More Info
|
| CIPLA | 1,409.40 0.28% | 1,409.15 0.21% |
|
More Info
|
| DIVIS LABORATORIES | 4,025.35 4.81% | 4,016.35 4.49% |
|
More Info
|
| GLENMARK PHARMA | 1,080.05 0.05% | 1,079.35 -0.09% |
|
More Info
|
| LUPIN | 1,615.85 1.31% | 1,615.95 1.35% |
|
More Info
|
| NIFTY 50 | Not Listed | 22,419.95 -0.67% |
|
More Info
|
| NIFTY PHARMA | Not Listed | 18,994.65 0.62% |
|
More Info
|
| PIRAMAL ENTERPRISES | 925.05 1.90% | 925.75 1.96% |
|
More Info
|
| S&P BSE SENSEX | 73,730.16 -0.82% | Not Listed |
|
More Info
|
| SUN PHARMA | 1,504.25 -1.07% | 1,506.55 -0.89% |
|
More Info
|
| ZYDUS LIFESCIENCES | 947.90 -0.32% | 948.00 -0.34% |
|
More Info
|
BSE prices: April 26, 2024 (Close) NSE prices: April 26, 2024 (Close)
NIFTY Pharma Stocks Update
Within the NIFTY Pharma Index, the top gainers were BIOCON (up 5.3%) and DIVIS LABORATORIES (up 4.8%). On the other hand, SUN PHARMA (down 1.1%) and ZYDUS LIFESCIENCES (down 0.3%) were among the top losers.
Meanwhile, the benchmark NIFTY 50 was at 22,419.9 (down 0.7%).
Before you go, here are the upcoming corporate actions for NIFTY Pharma stocks.
Upcoming Quarterly Results
| COMPANY | PRICE (Rs) | CHANGE (%) | RESULT DATE |
|---|---|---|---|
| LUPIN | 1,615.85 | 1.31 | 6-May-24 |
| CIPLA | 1,409.40 | 0.28 | 10-May-24 |
| BIOCON | 307.00 | 5.25 | 16-May-24 |
List of All Upcoming Quarterly Results
FAQs
What is Nifty pharma index?
The Nifty pharma index captures the performance of listed Indian companies in the pharmaceutical sector.
The index comprises of 10 stocks that are listed on the National Stock Exchange (NSE).
The index is calculated using a free float market capitalization method.
To filter the best quality stocks from the Nifty pharma index, check out Equitymaster’s Indian stock screener. This screener also allows you to screen stocks based on your own criteria.
Also take a look at our detailed analysis of the best pharma stocks in India.
Which are the top Nifty pharma companies?
Based on marketcap, these are the top 5 companies in the Nifty pharma index:
- #1 SUN PHARMA
- #2 CIPLA
- #3 DIVIS LABORATORIES
- #4 ZYDUS LIFESCIENCES
- #5 LUPIN
You can see the full list of the Nifty pharma stocks here.
And for a fundamental analysis of the above companies, check out Equitymaster’s Indian stock screener which has a separate screen for top pharma companies in India.
What is the price of Nifty pharma index live today?
The NIFTY PHARMA last traded at 18,994.7. It was up 0.6% over its previous close.
Within the NIFTY Pharma Index, the top gainers were BIOCON (up 5.3%) and DIVIS LABORATORIES (up 4.8%). On the other hand, SUN PHARMA (down 1.1%) and ZYDUS LIFESCIENCES (down 0.3%) were among the top losers.
For more, please visit the Nifty pharma index live chart and also check out our pharma sector report.
Can we buy the Nifty pharma index?
The Nifty pharma index is a collection of stocks and not a security that is traded on any stock exchange. Hence, we cannot buy it directly.
However, there are ways in which one can invest in the Nifty pharma index.
One can invest in index funds or ETFs representing the index or buying future and options for it.
Which are the other important indices one should track?
Well, it depends on what your goals are.
Having said that, the two key indices to track are the BSE Sensex and the NSE Nifty.
However, these two indices are considered to be too narrow by some, since they only track 30 and 50 stocks, respectively.
For broader tracking, you could use the BSE 200, BSE 500 or even the NSE 500 index.
Some popular market cap based indices include BSE Smallcap index and BSE Midcap index , among others.
Which other sectoral indices should one track?
It depends on one's specific interests and investment goals.
Some popular sectoral indices to track in addition to the broader market indices are Nifty PSU bank index , Nifty realty index , Nifty metal index and Nifty FMCG index .
It's important to research and understand the industries and companies included in each sectoral index to make informed investment decisions.
Today's Market
![Sensex Today Tanks 609 Points | Auto Stocks Drag | Bajaj Finance, L&T Technology Sink 7%]()
Sensex Today Tanks 609 Points | Auto Stocks Drag | Bajaj Finance, L&T Technology Sink 7%(Closing)
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Multibagger Penny Stocks
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Best Small-cap Stocks to Buy
- Best Bluechip Stocks to Buy
- Guide to Penny Stocks
- How to Invest in the Share Market
- Warren Buffett - The Value Investor
- Pick the Best Multibagger Stocks
TRENDING TOPICS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407
Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com
LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.